Mochida Pharmaceutical Co., Ltd. (FRA:MFY)
Germany · Delayed Price · Currency is EUR 19.30
+0.40 (2.12%)
At close: Jan 30, 2026
Mochida Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 109,048 | 105,159 | 102,885 | 103,261 | 110,179 | 102,995 | |
Revenue Growth (YoY) | 4.35% | 2.21% | -0.36% | -6.28% | 6.98% | 1.18% |
Cost of Revenue | 53,693 | 51,371 | 50,815 | 48,146 | 50,626 | 48,203 |
Gross Profit | 55,355 | 53,788 | 52,070 | 55,115 | 59,553 | 54,792 |
Selling, General & Admin | 34,377 | 33,985 | 33,713 | 33,324 | 32,866 | 31,939 |
Research & Development | 11,676 | 11,676 | 12,554 | 13,283 | 12,295 | 10,849 |
Operating Expenses | 46,053 | 45,661 | 46,267 | 46,607 | 45,161 | 42,788 |
Operating Income | 9,302 | 8,127 | 5,803 | 8,508 | 14,392 | 12,004 |
Interest Expense | -3 | -3 | -2 | - | - | - |
Interest & Investment Income | 505 | 420 | 365 | 340 | 286 | 257 |
Earnings From Equity Investments | -583 | -618 | -168 | - | - | - |
Currency Exchange Gain (Loss) | -198 | - | -60 | -36 | - | -102 |
Other Non Operating Income (Expenses) | 144 | 141 | 99 | 273 | 120 | 100 |
EBT Excluding Unusual Items | 9,167 | 8,067 | 6,037 | 9,085 | 14,798 | 12,259 |
Gain (Loss) on Sale of Investments | - | - | 100 | - | 526 | - |
Gain (Loss) on Sale of Assets | -3 | -15 | 22 | -54 | -5 | -108 |
Asset Writedown | - | - | - | - | -107 | - |
Other Unusual Items | - | - | 1 | 13 | -621 | -252 |
Pretax Income | 9,164 | 8,052 | 6,160 | 9,044 | 14,591 | 11,899 |
Income Tax Expense | 2,448 | 2,367 | 1,613 | 2,395 | 4,022 | 3,312 |
Net Income | 6,716 | 5,685 | 4,547 | 6,649 | 10,569 | 8,587 |
Net Income to Common | 6,716 | 5,685 | 4,547 | 6,649 | 10,569 | 8,587 |
Net Income Growth | 48.13% | 25.03% | -31.61% | -37.09% | 23.08% | 86.76% |
Shares Outstanding (Basic) | 35 | 35 | 36 | 37 | 38 | 39 |
Shares Outstanding (Diluted) | 35 | 35 | 36 | 37 | 38 | 39 |
Shares Change (YoY) | -0.09% | -1.15% | -3.49% | -2.47% | -1.37% | -1.23% |
EPS (Basic) | 189.45 | 160.36 | 126.79 | 178.93 | 277.39 | 222.27 |
EPS (Diluted) | 189.45 | 160.36 | 126.79 | 178.93 | 277.39 | 222.27 |
EPS Growth | 48.26% | 26.48% | -29.14% | -35.49% | 24.80% | 89.09% |
Free Cash Flow | 2,808 | 7,194 | -9,776 | 5,131 | 4,471 | 7,263 |
Free Cash Flow Per Share | 79.21 | 202.93 | -272.59 | 138.08 | 117.34 | 188.00 |
Dividend Per Share | 80.000 | 80.000 | 80.000 | 80.000 | 90.000 | 90.000 |
Dividend Growth | - | - | - | -11.11% | - | 12.50% |
Gross Margin | 50.76% | 51.15% | 50.61% | 53.37% | 54.05% | 53.20% |
Operating Margin | 8.53% | 7.73% | 5.64% | 8.24% | 13.06% | 11.65% |
Profit Margin | 6.16% | 5.41% | 4.42% | 6.44% | 9.59% | 8.34% |
Free Cash Flow Margin | 2.57% | 6.84% | -9.50% | 4.97% | 4.06% | 7.05% |
EBITDA | 12,245 | 11,067 | 8,611 | 11,180 | 17,081 | 14,746 |
EBITDA Margin | 11.23% | 10.52% | 8.37% | 10.83% | 15.50% | 14.32% |
D&A For EBITDA | 2,943 | 2,940 | 2,808 | 2,672 | 2,689 | 2,742 |
EBIT | 9,302 | 8,127 | 5,803 | 8,508 | 14,392 | 12,004 |
EBIT Margin | 8.53% | 7.73% | 5.64% | 8.24% | 13.06% | 11.65% |
Effective Tax Rate | 26.71% | 29.40% | 26.19% | 26.48% | 27.57% | 27.83% |
Advertising Expenses | - | 5,065 | 4,966 | - | 4,251 | 4,339 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.